Innovative Medicines Initiative

Colm Carroll
27.11.2014 - London

IMI – Europe's partnership for health



imi innovative medicines initiative

An international, cross-sector community



Over 7 000 researchers

59 public-private consortia

innovative medicines initiative

Typical IMI 2 project life cycle



innovative medicines initiative

IMI2 Call 2: Ebola+ programme

Topics

- Topic 1: Vaccine development Phase I, II, and III
- Topic 2: Manufacturing capability
- Topic 3: Stability of vaccines during transport and storage
- Topic 4: Deployment and compliance of vaccination regimens
- Topic 5: Rapid diagnostic tests

Budget

- Indicative IMI financial contribution: **up to €140 million**
- Indicative contribution by EFPIA companies: **approx. €140 million**

Deadline: 1 December

imi innovative medicines initiative

Upcoming Topics – IMI2 Calls 3 & 4

3.1 Remote Assessment of Disease and Relapse – CNS

3.2 Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification

3.3 Linking clinical neuropsychiatry and quantitative neurobiology

3.4 The consistency approach to quality control in vaccine manufacture

3.5 Pertussis vaccination research

3.6 Knowledge repository to enable patient-focused medicine development

4.1 Enabling platform on medicines adaptive pathway to patient

Expected Call Launch: 12 December 2014

innovative medicines initiative

1. Remote Assessment of Diseases And Relapse (RADAR) Programme

Challenges in Managing Chronic Disease

- Physician visits are **time-limited evaluations** based on **subjective observations** of both the patient and the physician
- **Changes in disease state** for each of these diseases can occur on timescales much **shorter** than the interval between physician visits
- Through technological advances over the last decade it is now possible to **objectively, remotely, and continuously measure** aspects of patient **physiology, behavior and symptoms**

imi innovative medicines initiative

RADAR Topic 1 – CNS

Indicative budget: €11m IMI, €11m Industry contribution

- **Develop and validate the science** of using **biosignatures to characterise disease** and **predict changes** in CNS diseases
- Understand the **regulatory pathways**
- Develop **standards** that enable **seamless integration** of sensor, data capture, data management, & analysis technologies
- Expected **applicant consortium:**
  - **Academic, clinical and disease area experts**
  - **Device and sensor companies**
  - **IT/ analytics expertise**
  - **Regulatory and health-care systems expertise**

imi innovative medicines initiative

Stay in touch

- Visit our website
  www.imi.europa.eu
- Sign up to our newsletter
  bit.ly/IMInewsletter
- Follow us on Twitter
  @IMI_JU
- Join our LinkedIn group
  bit.ly/LinkedInIMI
- E-mail us
  infodesk@imi.europa.eu

innovative medicines initiative

Thank you

www.imi.europa.eu
@IMI_JU